Trials with ONC-392
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–1 of 1
NCT04140526
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants …